Skip Navigation
Skip Website Tools

Contact Info

Nicole Doria-Rose, Ph.D.
Vaccine Research Center
40 Convent Drive
Building 40, Room 5510
Bethesda, MD 20892-3005
Phone: 301-594-8723
Fax: 301-480-0274
Nicole.doriarose@nih.gov​

Vaccine Research Center (VRC)

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Nicole Doria-Rose, Ph.D.

Chief, Humoral Immunology Core

Major Areas of Research

  • Developing and applying assays to evaluate HIV-1- specific antibody responses, during natural infection and after immunization
 

Program Description

The Humoral Immunology Core (HIMC) is responsible for providing antibody binding and neutralization data to the Humoral Immunology Section (HIMS) and other VRC laboratories. It routinely performs assays on clinical and preclinical specimens from both infection and immunization studies. The HIMC develops and applies neutralization assays to evaluate HIV-1- specific antibody responses, and binding and functional assays to monitor HIV-1 humoral immune responses. In addition, the HIMC produces experimental reagents (such as monoclonal antibodies), develops new assays, and provides results of current assays, data quality assurance, and data interpretation to other VRC investigators.

In particular, the core has developed and standardized molecular reporter virus assays to study HIV-1 neutralizing antibodies. Such assays allow the study of diverse viruses isolated from various regions of the world in order to understand the effect of genetic and antigenic diversity and the impact of viral escape on neutralizing antibody responses. The application of such assays allows the study of the antibody specificities in sera from small animals, non-human primates and healthy human volunteers, as well as sera from HIV-1-infected donors. The viral epitopes targeted by serum antibodies can be specifically mapped, and these data can be used to assess specific vaccine immunogens and to help understand the development of neutralizing activity during the course of infection.

Biography

Dr. Doria-Rose obtained her Bachelor of Arts, Biology, in 1991 and her Ph.D. in 1998 from Cornell University, Ithaca, New York, training under Dr. Volker Vogt, Department of Biochemistry, Molecular and Cell Biology. From 1998 to 2003, Dr. Doria-Rose worked as a postdoctoral scientist in the laboratory of Dr. Nancy Haigwood at the Seattle Biomedical Research Institute and the Department of Pathobiology, University of Washington. She was promoted to the position of associate scientist in 2003. While working as a post-doctoral fellow, Dr. Doria-Rose was also appointed as associate faculty, science department, Shoreline Community College, Shoreline, Washington, in 2000. Dr. Doria-Rose joined the National Institutes of Health in 2006 as a senior research fellow, NIAID Laboratory of Immunoregulation. In 2011, she became a staff scientist at the VRC, where she has worked on isolating new, potent anti-HIV monoclonal antibodies and studying their development over time. In 2012, she was promoted to the position of chief, Humoral Immunology Core.

Selected Publications

Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Nisc Comparative Sequencing, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 1;509(7498):55-62.​

Georgiev IS, Doria-Rose NA, Zhou T, Kwon YD, Staupe RP, Moquin S, Chuang GY, Louder MK, Schmidt SD, Altae-Tran HR, Bailer RT, McKee K, Nason M, O'Dell S, Ofek G, Pancera M, Srivatsan S, Shapiro L, Connors M, Migueles SA, Morris L, Nishimura Y, Martin MA, Mascola JR, Kwong PD. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science. 2013 May 10;340(6133):751-6.

Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol. 2013 Jul;20(7):804-13.

Doria-Rose NA, Georgiev I, O'Dell S, Chuang GY, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF, Burton DR, Koff WC, Kwong PD, Mascola JR. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol. 2012 Aug;86(15):8319-23.

Doria-Rose NA, Louder MK, Yang Z, O'Dell S, Nason M, Schmidt SD, McKee K, Seaman MS, Bailer RT, Mascola JR. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol. 2012 Mar;86(6):3393-7.

Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, Bhattacharya T, Migueles SA, Wyatt RT, Korber BT, Mascola JR, Connors M. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol. 2010 Feb;84(3):1631-6.

 

For more information on research conducted by Nicole Doria-Rose, Ph.D. visit the Humoral Immunology Section.

Last Updated August 25, 2014